Sunovion Pharmaceuticals Inc.

330 articles with Sunovion Pharmaceuticals Inc.

• 

  Clinical Catch-Up: May 3-7

  5/10/2021

  It was a busy week for clinical trial news. Here’s a look.

• Sunovion Presents Data From Marketed and Late-Stage Development Psychiatric Compounds At The American Psychiatric Association (APA) Annual Meeting 2021

  5/3/2021

  - An analysis compares clinical safety data of investigational agent SEP-363856 with real-world safety reports of approved antipsychotics, highlighting differentiated profile of SEP-363856 - - New post-hoc analysis indicates treatment with Latuda ® (lurasidone HCI) improved psychic and somatic anxiety in adults with bipolar depression -

• 

  Clinical Catch-Up: December 14-18

  12/21/2020

  Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look.

• Sunovion Highlights Data from Its Late-Stage Psychiatric Medicine Pipeline at the American College of Neuropsychopharmacology (ACNP) Annual Meeting 2020

  12/10/2020

  Sunovion Pharmaceuticals Inc. (Sunovion) today announced that new data and analyses of late-stage compounds SEP-363856 and SEP-4199 were presented at the 59th Annual Meeting of the American College of Neuropsychopharmacology virtual meeting, which took place December 6-9.

• Sunovion Marks 10 Years of Addressing Serious Medical Conditions That Impact the Lives of Millions Worldwide

  10/26/2020

  Sunovion Pharmaceuticals Inc. announced that the company is marking ten years since it was established in October 2010.

• Sunovion Announces the Commercial Launch of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes

  10/5/2020

  Sunovion Pharmaceuticals Inc. (Sunovion) today announced that KYNMOBI™ (apomorphine HCI) sublingual film is now available in the U.S. by prescription for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). KYNMO

• Sunovion Answers Is Named a J.D. Power 2020 Certified Customer Service ProgramSM

  9/22/2020

  Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the Company’s support services program, Sunovion Answers, has been named as a J.D. Power 2020 Certified Customer Service Pro

• XENLETA® (lefamulin) Receives Health Canada Approval for Treatment of Community Acquired Pneumonia-XENLETA to be marketed exclusively in Canada by Sunovion Pharmaceuticals Canada Inc.

  7/16/2020

  Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sunovion Pharmaceuticals Canada Inc., has received approval from Health Canada to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults.

• 

  Clinical Catch-Up: July 6-10

  7/13/2020

  Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.

• Sunovion Announces Topline Results from Global Phase 2 Study of SEP-4199 in Patients with Bipolar I Depression

  7/6/2020

  Sunovion Pharmaceuticals Inc. (Sunovion) today announced topline results from study SEP380-201 , a global, multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy, safety, and tolerability of treatment with SEP-4199, an investigational oral medicine for the treatment of major depressive episodes associated with bipolar I disorder (bipolar I depression). SEP-4199 is

• Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals

  6/18/2020

  Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. Both companies are subsidiaries of Sumitomo Dainippon Pharma Co., Ltd. The co-promotion agreement will enable

• AMSA and Sunovion Team Up For Second Year of Neuroscience Peer Teaching Program While Transitioning to Remote Learning Experience

  6/17/2020

  The Advanced Math & Science Academy Charter School (AMSA) and Sunovion Pharmaceuticals Inc. (Sunovion) today announced completion of the second year of a program to help students understand Science, Technology, Engineering and Math (STEM) life science career paths within a pharmaceutical company and foster a deeper knowledge of neuroscience. Six AMSA upper school level students, five seniors and one junior, we

• Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes

  6/15/2020

  Sunovion Announces Health Canada Approval of KYNMOBI™ (apomorphine hydrochloride) Soluble Film for the Treatment of Parkinson’s Disease OFF Episodes - First and only sublingual therapy approved for the on-demand treatment of Parkinson’s disease OFF episodes - MISSISSAUGA, Ontario--( BUSINESS WIRE )-- Sunovion Pharmaceuticals Inc. (Sunovion) announced today that Health Canada has approved KYNMOBI™ (apomorphine HCI) soluble film for the acute, inter

• 

  FDA Gives Thumbs-Up to Sunovion's Under-the-Tongue Parkinson's Drug

  5/22/2020

  “Today’s approval of Kynmobi advances treatment options for people with Parkinson’s disease who experience OFF episodes and the associated disruption of everyday activities,” said Antony Loebel, Sunovion’s president and chief executive officer.

• Sunovion Announces U.S. FDA Approval of KYNMOBI™ (apomorphine hydrochloride) Sublingual Film for the Treatment of Parkinson’s Disease OFF Episodes

  5/21/2020

  Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) has approved KYNMOBI™ (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD).

• Sunovion Discontinues Dasotraline Program

  5/13/2020

  Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has withdrawn the New Drug Applications (NDAs) for dasotraline, a novel dopamine and norepinephrine reuptake inhibitor (DNRI), for the treatment of moderate-to-severe binge eating disorder (BED) and attention deficit hyperactivity disorder (ADHD). While Sunovion considers dasotraline to be a promising, novel treatment for BED and ADHD, we believe t

• 

  FDA Action Alert: Blueprint, Bristol Myers Squibb, Clovis and Sunovion

  5/11/2020

  Despite the COVID-19 pandemic, the U.S. Food and Drug Administration has managed to stay fairly on track in terms of evaluating new drug and supplemental new drug applications. Here’s a look at what’s on the schedule for the next two weeks.
• 

  Clinical Catch-Up: April 13-17

  4/20/2020

  There’s plenty of news related to clinical trials related to COVID-19, but it does seem to be drowning out non-COVID-19-related clinical trials. Here’s a look.

• Sunovion Announces FDA Filing Acceptance of Resubmitted New Drug Application for Apomorphine Sublingual Film

  12/20/2019

  Sunovion Pharmaceuticals Inc. (Sunovion) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for apomorphine sublingual film (APL-130277) to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease (PD), which was resubmitted on November 21, 2019.

• Sunovion Announces Results from Its Open-Label Extension Study of SEP-363856 in Schizophrenia

  12/12/2019

  Sunovion Pharmaceuticals Inc. (Sunovion) today announced results from study SEP361-202 which evaluated the long-term safety and effectiveness of SEP-363856, a novel non-dopamine 2 (D2) agent under investigation for the treatment of patients with schizophrenia.